Hinni Michael L, Salassa John R, Grant David G, Pearson Bruce W, Hayden Richard E, Martin Alexios, Christiansen Hans, Haughey Bruce H, Nussenbaum Brian, Steiner Wolfgang
Department of Otolaryngology, Head and Neck Surgery, Mayo Clinic Arizona, Phoenix, AZ 85054, USA.
Arch Otolaryngol Head Neck Surg. 2007 Dec;133(12):1198-204. doi: 10.1001/archotol.133.12.1198.
To report the oncologic and functional outcomes of transoral laser microsurgery (TLM) in the treatment of advanced laryngeal cancer.
Prospective case series study.
Multi-institution (academic, tertiary referral centers).
A total of 117 patients with pathologically confirmed T2 to T4 lesions, stage III or stage IV, glottic or supraglottic carcinoma of the larynx were treated with TLM from 1997 to 2004. All patients had a minimum follow-up period of 2 years.
Transoral laser microsurgery in 117 patients, neck dissection in 91 patients, and adjuvant radiotherapy in 45 patients.
End points analyzed included laryngeal preservation, overall survival, disease-free survival, local control, locoregional control, and distant metastases. Postoperative complications, tracheotomy rate, and feeding-tube dependence were also examined.
The median follow-up period among surviving patients was 5 years. At 2 years, the percentage of patients with an intact larynx after treatment was 92%. The 2-year local control and locoregional control rates were 82% and 77%, respectively. The 2-year disease-free and overall survival rates were 68% and 75%, respectively. The 5-year Kaplan-Meier estimates were local control, 74%; locoregional, control, 68%; disease-free survival, 58%; overall survival, 55%; and distant metastases, 14%. Four patients (3%) experienced treatment-related deaths. Seven patients (6%) experienced a postoperative hemorrhage. Of those patients with organ preservation and no disease recurrence, 2 patients (3%) were tracheotomy dependent, and 4 patients (7%) were feeding-tube dependent.
In patients with advanced laryngeal cancer, TLM with or without radiotherapy is a valid treatment strategy for organ preservation. Furthermore, low morbidity and mortality and excellent oncologic and functional outcomes make TLM an attractive therapeutic option.
报告经口激光显微手术(TLM)治疗晚期喉癌的肿瘤学及功能学结果。
前瞻性病例系列研究。
多机构(学术性三级转诊中心)。
1997年至2004年期间,共有117例经病理确诊为T2至T4期、III期或IV期的声门型或声门上型喉癌患者接受了TLM治疗。所有患者的最短随访期为2年。
117例患者接受经口激光显微手术,91例患者接受颈部清扫术,45例患者接受辅助放疗。
分析的终点指标包括喉保留情况、总生存率、无病生存率、局部控制率、区域控制率和远处转移情况。还检查了术后并发症、气管切开率和鼻饲管依赖情况。
存活患者的中位随访期为5年。治疗后2年时,喉部完整的患者比例为92%。2年局部控制率和区域控制率分别为82%和77%。2年无病生存率和总生存率分别为68%和75%。5年的Kaplan-Meier估计值为:局部控制率74%;区域控制率68%;无病生存率58%;总生存率55%;远处转移率14%。4例患者(3%)死于与治疗相关的原因。7例患者(6%)术后出血。在保留器官且无疾病复发的患者中,2例患者(3%)依赖气管切开,4例患者(7%)依赖鼻饲管。
对于晚期喉癌患者,TLM联合或不联合放疗是一种有效的器官保留治疗策略。此外,低发病率和死亡率以及良好的肿瘤学及功能学结果使TLM成为一种有吸引力的治疗选择。